Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Nerviano Medical Sciences divulges new PARP-1 inhibitors

Feb. 10, 2011

AstraZeneca to withdraw NDA for anticancer drug Iressa

Feb. 10, 2011

PharmaMar begins phase I trial of antitumor agent PM-060184

Feb. 10, 2011

CytRx reports preclinical data on bafetinib in cancer-related bone loss

Feb. 9, 2011

Treatment begins in phase I elesclomol trial in acute myeloid leukemia

Feb. 9, 2011

HspB8 blocks autophagy in breast cancer cells, conferring resistance to tamoxifen

Feb. 9, 2011

Harbor BioSciences completes phase I/IIa Apoptone trial in prostate cancer

Feb. 8, 2011

TEAM trial compares exemestane alone to sequential tamoxifen/exemestane therapy in breast cancer

Feb. 8, 2011

Aveo's anticancer antibody AV-299 to be called ficlatuzumab

Feb. 7, 2011

AstraZeneca discontinues ENTHUSE Study 15 of zibotentan in prostate cancer

Feb. 7, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.